Clinical Trials Logo

Filter by:
NCT ID: NCT06390995 Recruiting - Ovarian Cancer Clinical Trials

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time. The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle. The participant will be in the study for about 9 months in Phase 1 Part and for about 24 months in Phase 2 Part. The study doctors will check for side effects from the study treatments.

NCT ID: NCT06389487 Recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Start date: April 29, 2024
Phase: Phase 3
Study type: Interventional

The aim of this study is to demonstrate the immune response and to evaluate safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for respiratory syncytial virus (RSV) disease, compared to older adults (OA) (>=) 60 YOA and above

NCT ID: NCT06388967 Recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Detection Consortium

PCDC
Start date: March 15, 2023
Phase:
Study type: Observational

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

NCT ID: NCT06382987 Recruiting - Plaque Psoriasis Clinical Trials

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

RePhlect
Start date: January 22, 2024
Phase:
Study type: Observational [Patient Registry]

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

NCT ID: NCT06381648 Recruiting - Cholangiocarcinoma Clinical Trials

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

LyMIC
Start date: April 15, 2023
Phase:
Study type: Observational

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

NCT ID: NCT06377592 Recruiting - Clinical trials for Bacterial Infections

Development and Accuracy Evaluation of Gram Staining Analysis AI

Start date: May 10, 2023
Phase:
Study type: Observational

The investigators use Gram-stained specimens provided from clinical settings to develop and evaluate the accuracy of Gram staining analysis AI

NCT ID: NCT06372613 Recruiting - Clinical trials for Ulcerative Colitis in Histologic Remission

Association Between LRG and Histologic Remission in Ulcerative Colitis

Start date: February 25, 2024
Phase:
Study type: Observational

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.

NCT ID: NCT06372496 Recruiting - Asthma Clinical Trials

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Start date: April 16, 2024
Phase: Phase 4
Study type: Interventional

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

NCT ID: NCT06368102 Recruiting - Clinical trials for Surgical Site Infection

Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery

Start date: May 2, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the incidence of surgical site infection (SSIs) after third molar surgery for different duration of intravenous ampicillin administration.

NCT ID: NCT06362044 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan

Start date: June 7, 2023
Phase:
Study type: Observational

Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival. This study will evaluate the participant's related outcomes and experience of CLL in adult participants who are treated in the Japan. Study participants will receive oral treatments of Venetoclax±Rituximab for CLL as prescribed by their study doctor in accordance with approved local label. Adult participants prescribed various treatments Venetoclax±Rituximab will be enrolled. Around 89 participants will be enrolled in the study in sites in Japan. Participants will receive oral venetoclax tablets ± intravenously (IV) infused rituximab treatments for CLL according to the approved local label. The overall study duration will be 27 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.